Migden, M. R., Berkin, C., Chang, A. L. and al., E. (2018) “Interim Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Antibody to Programmed Death-1, in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma”, SKIN The Journal of Cutaneous Medicine, 2, p. S77. doi: 10.25251/skin.2.supp.77.